Shares of Tango Therapeutics (NASDAQ: TNGX) were up 16.7% for the week as of Thursday’s close, according to data provided by S&P Global Market Intelligence. The clinical-stage biotech company’s stock closed at $7.06 last week, then rose as high as $8.53 on Tuesday. The stock is up 13% so far this year.
The CRISPR gene-editing stock kept climbing because the company announced last week that the Food and Drug Administration (FDA) had cleared the company’s Investigational New Drug (IND) application for cancer therapy TNG348. The company said it will start a phase 1/2 clinical trial for TNG348 to treat BRCA mutant and other homologous recombination deficient cancers early next year.
The company is beginning to see momentum in terms of its clinical pipeline, with TNG348 the latest therapy to begin early-stage trials. The company also has TNG908 and TNG462 in phase 1/2 trials to treat patients with MTAP-deleted tumors. Tango also has TNG260 in a phase 1/2 trial as a combination therapy with pembrolizumab to treat STK11-mutant cancers.
Like any clinical-stage company, there’s plenty of risk to go with the upside for Tango. The company doesn’t have any product revenue yet, but as of the second quarter, it said it had $9.6 million in collaboration revenue, up from $5.7 million in the same period last year. It also reported $310.7 million in cash, enough, it said, to fund operations into 2026, and that was before a $80 million private stock sale.
It’s worth noting that the company is also seen as a potential buyout candidate, another reason to buy and hold the stock despite its risks.
10 stocks we like better than Tango Therapeutics
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now… and Tango Therapeutics wasn’t one of them! That’s right — they think these 10 stocks are even better buys.
*Stock Advisor returns as of September 11, 2023
Jim Halley has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
—
Blog powered by G6
Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.
For any inquiries, please contact [email protected]
